New properties of old drugs in the SARS-CoV-2 era (post-release)
References
1. Moore J., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. DOI: 10.1126/science.abb8925.
2. Лабори А. Регуляция обменных процессов. М.: Медицина; 1970. [Labori A. Regulation of metabolic processes. M.: Medicine; 1970 (in Russ.)].
3. Tracey K.J. The inflammatory reflex. Nature. 2002;420(6917):853–859. DOI: 10.1038/nature01321.
4. Виноградов В.М. Повышение резистентности организма к экстремальным воздействиям. Кишинев: Штиинца; 1973. [Vinogradov V.M. Increasing the body’s resistance to extreme influences. Chisinau: Shtiintsa; 1973 (in Russ.)].
5. Ungerstedt J.S., Blömback M., Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131(1):48–52. DOI: 10.1046/j.1365-2249.2003.02031.x.
6. Badawy A.A. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Biosci Rep. 2020;40(10):BSR20202856. DOI: 10.1042/BSR20202856.
7. Miller A., Wentzel G., Richards A. COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Med Hypotheses. 2020;144:110044. DOI: 10.1016/j.mehy.2020.110044.
8. Бузанов Д.В. Ранняя респираторная реабилитация при тяжелом COVID-19. Материалы X Балтийского форума «Актуальные проблемы анестезиологии и реаниматологии». Светлогорск, 30.06.21–3.07.21. [Buzanov D.V. Early respiratory rehabilitation for severe COVID-19. Materials of the 10th Baltic Forum "Actual problems of anesthesiology and resuscitation". Svetlogorsk, 30.06.21–3.07.21 (in Russ.)].
9. Афанасьев В.В., Баранцевич Е.Р., Вишневецкая Т.П. Азбука цитопротекции. СПб.: Стелла; 2016. [Afanasyev V.V., Barantsevich E.R., Vishnevetskaya T.P. The alphabet of cytoprotection. SPb.: Stella; 2016 (in Russ.)].
10. Денисенко П.П. Роль холинореактивных систем в регуляторных процессах. М.: Медицина; 1980. [Denisenko P.P. The role of cholinergic systems in regulatory processes. M.: Medicine; 1980 (in Russ.)].
11. Афанасьев В.В., Пугачева Е.Л., Баранцевич Е.Р. и др. Эффективность нейроцитопротекторов метаболической и медиаторной групп и их комбинаций при астеническом синдроме. Эффективная фармакотерапия. 2020;16(31):60–66. [Afanasiev V.V., Pugachyova Ye.L., Barantsevich Ye.R. et al. Efficaсy of neurocytoprotectors of metabolic and neurotransmitter mimic groups, and their pharmacological combinations in patients with asthenic syndrome. Effective Pharmacotherapy. 2020;16(31):60–66 (in Russ.)]. DOI: 10.33978/2307-3586-2020-16-31-60-66.
12. Artigas L., Coma M., Matos-Filipe P. et al. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One. 2020;15(10):e0240149. DOI: 10.1371/journal.pone.0240149.
13. Dobolyi A., Juhász G., Kovács Z., Kardos J. Uridine function in the central nervous system. Curr Top Med Chem. 2011;11(8):1058–1067. DOI: 10.2174/156802611795347618.
14. Mironova G.D., Belosludtseva N.V., Ananyan M.A. Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19) and its complications. Eur Rev Med Pharmacol Sci. 2020;24(16):8585–8591. DOI: 10.26355/eurrev_202008_22658.
2. Лабори А. Регуляция обменных процессов. М.: Медицина; 1970. [Labori A. Regulation of metabolic processes. M.: Medicine; 1970 (in Russ.)].
3. Tracey K.J. The inflammatory reflex. Nature. 2002;420(6917):853–859. DOI: 10.1038/nature01321.
4. Виноградов В.М. Повышение резистентности организма к экстремальным воздействиям. Кишинев: Штиинца; 1973. [Vinogradov V.M. Increasing the body’s resistance to extreme influences. Chisinau: Shtiintsa; 1973 (in Russ.)].
5. Ungerstedt J.S., Blömback M., Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131(1):48–52. DOI: 10.1046/j.1365-2249.2003.02031.x.
6. Badawy A.A. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Biosci Rep. 2020;40(10):BSR20202856. DOI: 10.1042/BSR20202856.
7. Miller A., Wentzel G., Richards A. COVID-19: NAD+ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. Med Hypotheses. 2020;144:110044. DOI: 10.1016/j.mehy.2020.110044.
8. Бузанов Д.В. Ранняя респираторная реабилитация при тяжелом COVID-19. Материалы X Балтийского форума «Актуальные проблемы анестезиологии и реаниматологии». Светлогорск, 30.06.21–3.07.21. [Buzanov D.V. Early respiratory rehabilitation for severe COVID-19. Materials of the 10th Baltic Forum "Actual problems of anesthesiology and resuscitation". Svetlogorsk, 30.06.21–3.07.21 (in Russ.)].
9. Афанасьев В.В., Баранцевич Е.Р., Вишневецкая Т.П. Азбука цитопротекции. СПб.: Стелла; 2016. [Afanasyev V.V., Barantsevich E.R., Vishnevetskaya T.P. The alphabet of cytoprotection. SPb.: Stella; 2016 (in Russ.)].
10. Денисенко П.П. Роль холинореактивных систем в регуляторных процессах. М.: Медицина; 1980. [Denisenko P.P. The role of cholinergic systems in regulatory processes. M.: Medicine; 1980 (in Russ.)].
11. Афанасьев В.В., Пугачева Е.Л., Баранцевич Е.Р. и др. Эффективность нейроцитопротекторов метаболической и медиаторной групп и их комбинаций при астеническом синдроме. Эффективная фармакотерапия. 2020;16(31):60–66. [Afanasiev V.V., Pugachyova Ye.L., Barantsevich Ye.R. et al. Efficaсy of neurocytoprotectors of metabolic and neurotransmitter mimic groups, and their pharmacological combinations in patients with asthenic syndrome. Effective Pharmacotherapy. 2020;16(31):60–66 (in Russ.)]. DOI: 10.33978/2307-3586-2020-16-31-60-66.
12. Artigas L., Coma M., Matos-Filipe P. et al. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One. 2020;15(10):e0240149. DOI: 10.1371/journal.pone.0240149.
13. Dobolyi A., Juhász G., Kovács Z., Kardos J. Uridine function in the central nervous system. Curr Top Med Chem. 2011;11(8):1058–1067. DOI: 10.2174/156802611795347618.
14. Mironova G.D., Belosludtseva N.V., Ananyan M.A. Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease 2019 (COVID-19) and its complications. Eur Rev Med Pharmacol Sci. 2020;24(16):8585–8591. DOI: 10.26355/eurrev_202008_22658.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
Распечатать